Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 6, 2014, Pages

  Mahapatra, Jataveda ^a   Quraishi, Seema N ^b   David, Anthony ^c   Sampson, Stephanie ^d   Adams, Clive E ^d  

^a Logan Hospital   (Australia)

^b SQ Therapy ^*  (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPENTIXOL DECANOATE; NEUROLEPTIC AGENT; PENFLURIDOL; PLACEBO; DELAYED RELEASE FORMULATION; FLUPENTIXOL; TRANQUILIZER;

BRIEF PSYCHIATRIC RATING SCALE; CLINICAL OUTCOME; DISEASE SEVERITY; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG INDUSTRY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; GOVERNMENT; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMATIC REVIEW; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; DELAYED RELEASE FORMULATION; PSYCHOTIC DISORDERS; THERAPEUTIC USE;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FLUPENTHIXOL; HUMANS; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; TRANQUILIZING AGENTS;

EID: 84942789137     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001470.pub2     Document Type: Review

References (207)

1. Cookson IB, Muthu MS, George A, Dewey M. High dose neuroleptic treatment of chronic schizophrenic inpatients. Research Communications in Psychology, Psychiatry and Behaviour 1983;8(4):305-15.
2. Cookson IB. The effects of a 50% reduction of cis(Z)-flupenthixol decanoate in chronic schizophrenic patients maintained on a high dose regime. International Clinical Psychopharmacology 1987;2:141-9.
3. Eberhard G. Depot antipsychotics in schizophrenic patients: a comparison between haloperidol decanoate and flupenthixol decanoate. International Clinical Psychopharmacology 1986;Suppl 1:27.
4. Eberhard G, Hellbom E. Haloperidol decanoate and flupenthixol decanoate in schizophrenia. A long-term double-blind cross-over comparison. Acta Psychiatria Scandinavica 1986;74:255-62.
5. Eufe R, Wegener G. Double-blind comparison of 2 depot neuroleptics (perphenazine enanthate and flupentixol decanoate) in chronic schizophrenia (author's transl) [Doppelblindvergleich von 2 depotneuroleptika (Perphenazin-onanthat und flupentixol-decaoat bei chronischer schizophrenie)]. Nervenarzt 1979;50:534-9.
6. Gerlach J, Kramp P, Kristjansen P, Lauritsen B, Luhdorf K, Munkvad I. Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. Acta Psychiatrica Scandinavica 1975;52:132-44.
7. Javed MA, Chaudhry MR. Double blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Pakistan Journal of Clinical Psychiatry 1991;1(2):69-74.
8. Johnson DAW, Ludlow JM, Street K, Taylor RDW. Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. British Journal of Psychiatry 1987;151:634-8.
9. Kelly HB, Freeman HL, Banning B, Schiff AA. Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. International Pharmacopsychiatry 1977;12:54-64.
10. Lundin L, Dencker SJ, Malm U. Community-based rehabilitation of schizophrenia. Nordisk Psykiatrisk Tidsskrift 1990;44:81-7.
11. Martyns-Yellowe IS. The decanoates of flupenthixol and clopenthixol in the treatment of chronic schizophrenic in-patients implications for community psychiatry. West African Journal of Medicine 1993;12(2):110-2.
12. McCreadie RG, Flanagan WL, McKnight J, Jorgensen A. High dose flupenthixol decanoate in chronic schizophrenia. British Journal of Psychiatry 1979;135:175-9.
13. Pinto R, Banerjee A, Ghosh N. A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. Acta Psychiatrica Scandinavica 1979;60:313-22.
14. Steinert J, Erba E, Pugh CR, Robinson C, Preist RG. A comparative trial of depot pipothiazine. Journal of International Medical Research 1986;14:72-7.
15. Wistedt B, Jorgensen A, Wiles D. A depot withdrawal study. Palsma concentration of fluphenazine and flupenthixol and relapse frequency. Psychopharmacology 1982;78:301-4.
16. Wistedt B, Wiles D, Jorgensen A. A depot neuroleptic withdrawal study neurological effects. Psychopharmacology 1983;80:101-5.
17. Wistedt B, Ranta J. Comparative double-blind study of flupenthixol decanoate and fluphenazine decanoate in the treatment of patients relapsing in a schizophrenic symptomatology. Acta Psychiatria Scandanavica 1983;67:378-88.
18. Arango C. Oral or depot antipsychotics for people with schizophrenia and a history of violence. Stanley Foundation Research Programs 1999.
19. Astrup C, Grimsgard A, Hebnes K, Kruse-Jensen A, Lid M. A study of flupenthixol decanoate and pipothiazine undecylenate in schizophrenics. Acta Psychiatrica Scandinavica 1974;50:481-91.
20. Bakke O. Clinical experience with DEPOT neuroleptics. Acta Psychiatrica Scandinavica Supplementum 1973;246:32-41. [MEDLINE: 4588180; MEDLINE: 74067198]
21. Barnes TR, Milavic G, Curson DA, Platt SD. Use of the Social Behaviour Assessment Schedule (SBAS) in a trial of maintenance antipsychotic therapy in schizophrenic. Social Psychiatry 1983;18(4):193-9. [MEDLINE: 6356386; MEDLINE: 84045025]
22. Benkert O, Müller-Siecheneder F, Wetzel H. Negative and depressive symptoms in acute schizophrenic episodes- do they improve under neuroleptic treatment?. 8th Congress of the Association of European Psychiatrists; 1996 Jul 7-12; London, UK. 1996. [MEDLINE: 6356386; MEDLINE: 84045025]
23. Bombin I, Arango C. Antipsychotic treatment adherence and violence in schizophrenia outpatients: a randomized prospective trial. European Neuropsychopharmacology 2004;14(Suppl.3):S289.
24. Burns T, Bale R. Clinical advantages of amisulpride in the treatment of acute schizophrenia. Journal of International Medical Research 2001;29(6):451-66. [MEDLINE: 12633119; MEDLINE: 22521194;: PSYCINFO]
25. Chanpattana W. ECT in Schizophrenia. Journal of the Psychiatric Association of Thailand 1999;44(2):156-70. [MEDLINE: 11305706; MEDLINE: 21200321]
26. Chanpattana W, Chakrabhand ML, Kirdcharoen N, Tuntirungsee Y, Techakasem P, Prasertsuk Y. The use of the stabilization period in electroconvulsive therapy research in schizophrenia: II. Implementation. Journal of the Medical Association of Thailand 1999;82(6):558-68. [MEDLINE: 10443077; MEDLINE: 99372024]
27. Chanpattana W, Chakrabhand ML, Kirdcharoen N, Tuntirungsee Y, Techakasem P, Prasertsuk Y. The use of the stabilization period in electroconvulsive therapy research in schizophrenia: II. Implementation. Journal of the Medical Association of Thailand 1999;82(6):558-68. [MEDLINE: 10443077; MEDLINE: 99372024]
28. Chanpattana W, Chakrabhand ML, Sackeim HA, Kitaroonchai W, Kongsakon R, Techakasem P, et al.Continuation ECT in treatment resistant schizophrenia: a controlled study. Journal of ECT 1999;15(3):178-92. [MEDLINE: 10492856; MEDLINE: 99422524]
29. Chanpattana W, Sackeim HA, Techakasem P, Chakrabhand S. ECT in schizophrenia. 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA. 1999. [MEDLINE: 10211147; MEDLINE: 99227593]
30. Chouinard G, Annable L, Kropsky M. A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. Journal of Clinical Pharmacology 1978;18(2-3):148-54. [MEDLINE: 24061; MEDLINE: 78109735;: PsycINFO]
31. Chowdhury MEH, Chacon C. Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. A double-blind comparative trial. Comprehensive Psychiatry 1980;21(2):135-9.
32. Classen W, Laux G. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatry 1988;21(6):295-7. [MEDLINE: 2907629; MEDLINE: 89221175]
33. Colonna L, Saleem P, Dondey Nouvel L, Rein W, Bartholome F, Boxus A, et al.Long term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. International Clinical Psychopharmacology 2000;15(1):13-22. [EMBASE: 2000039766; MEDLINE: 10836281; MEDLINE: 20294270]
34. Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clinical Neuropharmacology 1991;14(Suppl 2):S24-32. [MEDLINE: 1751940; MEDLINE: 92089872]
35. Cotes PM, Crow TJ, Johnstone EC. Serum prolactin as an index of dopamine receptor blockade in acute schizophrenia. British Journal of Clinical Pharmacology 1977;4:651P. [MEDLINE: 78020591; MEDLINE: 911637]
36. Coufal J, Novotny M. Fluphenazine and flupenthixol decanoate in psychiatric outpatients practice. Activa Nervosa Superior (Praha) 1981;23(4):269-71.
37. Crow TJ, Frith C, Johnstone EC. The clinical effects of the isomers of flupenthixol: the consequences of dopamine receptor blockade in acute schizophrenia (Proceedings). British Journal of Clinical Pharmacology 1977;4(5):648P. [MEDLINE: 78020591; MEDLINE: 911637]
38. Crow TJ, Johnstone EC. Stereochemical specificity in the antipsychotic effects of flupenthixol in man (Proceedings). British Journal of Pharmacology 1977;59(3):466P. [MEDLINE: 14758; MEDLINE: 77135570]
39. Crow TJ, MacMillan JF, Johnson AL, Johnstone EC. A randomised controlled trial of prophylactic neuroleptic treatment. British Journal of Psychiatry 1986;148(2):120-7. [MEDLINE: 2870753; MEDLINE: 86188455;: PASCAL]
40. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. II. The incidence of compliance problems, side-effects, neurotic symptoms and depression. British Journal of Psychiatry 1985;146:469-74. [MEDLINE: 3893599; MEDLINE: 85253529]
41. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine- placebo trial I. Course of illness, stability of diagnosis, and the role of a special maintenance clinic. British Journal of Psychiatry 1985;146:464-9. [MEDLINE: 3893598; MEDLINE: 85253528]
42. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. British Journal of Psychiatry 1985;146:474-80. [MEDLINE: 3893600; MEDLINE: 85253530]
43. Curson DA, Barnes TRE, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long term depot maintenance of chronic schizophrenic out-patients: the seven-year follow-up of the Medical Reseach Council fluphenazine/placebo trial. British Journal of Psychiatry 1985;146:464-80.
44. Dahmen N, Muller MJ, Germeyer S, Rujescu D, Anghelescu I, Hiemke C, et al.Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. Schizophrenia Research 2001;49:223-5. [MEDLINE: 11428346; MEDLINE: 21320214]
45. Davies LM, Lewis S, Jones PB, Barnes TRE, Gaughran F, Hayhurst K, et al.CUTLASS team. Cost-effectiveness of first- v second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. British Journal of Psychiatry 2007;191(July):14-22. [EMBASE: 2007328135; MEDLINE: 17602120]
46. Deberdt R, Elens P, Berghmans W, Heykants J, Woestnborghs R, Dreisens F, et al.Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. Acta Psychiatrica Scandinavica 1980;62:356-63. [MEDLINE: 6105763]
47. Demerdash A, Mazhar N, El-Hanbali M, Abou-Ghazala E. A double-blind trial of fluspirilene versus flupenthixol decanoate in the treatment of schizophrenic inpatients. Journal of Kuwait Medical Association 1981;15:7-16.
48. Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. II Factor analysis of the CPRS sub-scale for schizophrenia. Acta Psychiatrica Scandinavica Supplementum 1980;279:29-40.
49. Dencker SJ, Lepp M, Malm U. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. Acta Psychiatrica Scandinavica Supplementum 1980;4:10-39.
50. Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica, Supplementum 1980;279:64-76. [MEDLINE: 6105763;: ]
51. Dittmann RW, Geuppert MS, Diehl A, Hubrich P, Maraz, Gattaz WF. Olanzapine versus flupentixol in the treatment of inpatients with schizophrenia: a randomised double-blind trial. Schizophrenia Research 2001;49(1, 2):225. [MEDLINE: 11199942; MEDLINE: 21040726;: PsycINFO]
52. Dittmann RW, Diehl A, Hubrich P, Maras A, Gattaz WF. Randomized double-blind trial: olanzapine vs flupenthixol. 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [EMBASE: 2002386502]
53. Ehmann TS, Delva NJ, Beninger RJ. Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol. Journal of Clinical Psychopharmacology 1987;7(3):173-5. [MEDLINE: 3298328; MEDLINE: 87251434]
54. Eli Lilly, Company. HGBL: olz v flupentixol. Unpublished report 2001.
55. Faltus F, Soucek K. Treatment of schizophrenia using depot neuroleptics [Lecba schizofrenie depotnimi neuroleptiky]. Ceskoslovenska Psychiatrie 1976;72(3):170-5. [MEDLINE: 77001714; MEDLINE: 963807]
56. Floru L, Heinrich K, Wittek F. The problem of post-psychotic schizophrenic depressions and pharmacological induction. International Pharmacopsychiatria 1975;10:230-9.
57. Freeman HL. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies. International Clinical Psychopharmacology 1997;12(Suppl 2):S11-7. [MEDLINE: 9218163; MEDLINE: 97361269]
58. Frith CD, Stevens M, Johnstone EC, Crow TJ. Skin conductance responsivity during acute episodes of schizophrenia as a predictor of symptomatic improvement. Psychological Medicine 1979;9(1):101-6. [MEDLINE: 424477; MEDLINE: 79137443]
59. Gattaz WF, Diehl A, Geuppert MS, Hubrich P, Schmitt A, Linde I, et al.Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 2004;37(6):279-85. [EMBASE: 2004519197; MEDLINE: 15551194]
60. Genstahler BM. Flupentixol ist Risperidon ebenburtig. Pharmazeutische Zeitung 2001;146(42):30. [BIOSIS: 550227]
61. Giannelli A, Rabboni M, Zarattini F. Clinical profiles of action, individual treatment preferences, affects and contraindications of three depot neuroleptics compared in a multicentre trial [Profili clinici di azione, indicazioni preferenziali, effetti terapeutici e controindicazioni di tre neurolettici depot in trial multicentrico di confronto]. Rivista di Psichiatria 1990;25(1):7-24.
62. Glaser T, Philipp M, Lesch OM, Walter H, Patras L, Kurtz G, et al.Flupenthixol and risperidone: equivalent efficacy against negative symptoms in schizophrenia. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S120.
63. Glaser T, Philipp M, Mast O. Subjective experiences and satisfaction of schizophrenic patients treated with flupenthixol or risperidone: results of a double-blind trial. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S120.
64. Glick ID, Jacobs M, Lieberman J, Simpson G, Schooler NR. Prediction of short term outcome in schizophrenia: depressive symptoms, negative symptoms, and extrapyramidal signs. Treatment Strategies in Schizophrenia Collaborative Study Group. Psychopharmacology Bulletin 1989;25(3):344-7. [MEDLINE: 2626513; MEDLINE: 90175767]
65. Godleski LS, Goldsmith LJ, Zettwoch NC, Stikovac DC, Lewis SJ. Depot antipsychotic versus oral olanzapine treatment. 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA. 2000.
66. Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. Journal of Clinical Psychiatry 2003;64(2):119-22. [MEDLINE: 12633119; MEDLINE: 22521194;: PSYCINFO]
67. Gottfries CG. Clinical experiences with flupenthixol in psychiatric patients [Kliniska erfarenheter med flupenthixol pa ett psykosklientel]. Nordisk Psykiatrisk Tidsskrift 1967;21:430-6.
68. Gottfries CG. A double-blind investigation with flupenthixol and trifluoperazine at treatment of schizophrenic psychoses. Acta Psychiatrica Scandinavica Supplementum 1970;217:53. [MEDLINE: 211983; MEDLINE: 79020402]
69. Gottfries CG. Flupenthixol and flupenthixol decanoate with special reference to their antipsychotic effect. Acta Psychiatrica Belgica 1974;74(5):507-16.
70. Gottfries CG. Flupenthixol and trifluoperazine: a double-blind investigation in the treatment of schizophrenics. British Journal of Psychiatry 1971;119:547-8.
71. Gottfries CG, Green L. Flupenthixol decanoate in treatment of out-patients. Acta Psychiatrica Scandinavica 1974;Suppl 255:15-9.
72. Grunder G, Wetzel H, Schlosser R, Anghelescu I, Hillert A, Lange K, et al.Neuroendocrine response to antipsychotics: effects of drug type and gender. Biological Psychiatry 1999;45(1):89-97. [MEDLINE: 9894580; MEDLINE: 99111951]
73. Hamilton M, Card IR, Wallis GG, Mahmoud MR. A comparative trial of the decanoates of flupenthixol and fluphenazine. Psychopharmacology 1979;64:225-9.
74. Haslam MT, Bromham BM, Schiff AA. A comparative trial of fluphenazine decanoate and flupenthixol decanoate. Acta Psychiatrica Scandinavica 1975;51:92-100.
75. Hertling I, Dvorak A, Glaser T, Philipp M, Beneke M, Ramskogler K, et al.Influence of psychopathological symptoms on subjective quality of life of schizophrenic patients [Der einfluss psychopathologischer symptome auf die subjektive lebensqualitiat schizophrener patienten]. Psychopharmakotherapie 2003;10(4):151-8. [EMBASE: 2003494380]
76. Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Wetzel H, et al.Amisulpride vs flupentixol in the treatment of schizophrenia with predominant positive symptomatology: a controlled double-blind study. Neuropyschopharmacology 1994;10(3S):31s. [MEDLINE: 12633119; MEDLINE: 22521194;: PSYCINFO]
77. Hirsch SR, Jolley AG, Manchanda R, McRink A. Intermittent medication as an alternative to maintenance medication in the treatment of schizophrenia: a preliminary report [Fruehzeitige medikamentoese Intervention als Alternative zur Depot-Dauer-Medikation in der Schizophreniebehandlung Ein vorlaeufiger Bericht]. In: Boeker W, Brenner HD editor(s). Bewaltigung der Schizophrenie. Bern, Switzerland: Verlag Hans Huber, 1986:62-71. [PSYNDEX: 20591]
78. Huang J, Shuai Y, Cai C. A study on therapeutic efficacy of flupenthixol in treating chronic schizophrenics of type II. Chinese Journal of Neurology and Psychiatry 1995;28(5):269-72. [EMBASE: 1996089743; MEDLINE: ;: CAJ]
79. Ishimaru T, Kubo S, Ishikawa H, et al.Clinical evaluation on effect of flupentixol, a neuroleptic drug, on schizophrenia by double-blind controlled trial. Seishin Igaku (Clinical Psychiatry) 1971;13(7):739-47.
80. Johnson DA, Malik NA. A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. Acta Psychiatrica Scandinavica 1975;51:257-67.
81. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS. Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978;1(8069):848-51. [MEDLINE: 76797; MEDLINE: 78155245]
82. Johnstone EC, Frith CD, Gold A, Stevens M. The outcome of severe acute schizophrenic illnesses after one year. British Journal of Psychiatry 1979;134:28-33. [MEDLINE: 760920; MEDLINE: 79104450]
83. Jorgensen A, Overo KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta Psychiatrica Scandinavica 1980;61:41-54.
84. Jorgensen A, Anderson J, Bjorndal N, Dencker SJ, Lundin L, Malm U. Serum concentrations of cis(Z)-flupenthixol and prolactin in chronic schizophrenic patients treated with flupenthixol and cis(Z)-flupenthixol decanoate. Psychopharmacology 1982;77:58-65.
85. Joseph MH, Baker HF, Johnstone EC, Crow TJ. 3-Methoxy-4-hydroxyphenylglycol excretion in acutely schizophrenic patients during a controlled clinical trial of the isomers of flupenthixol. Psychopharmacology 1979;64(1):35-40. [MEDLINE: 113829; MEDLINE: 80013695]
86. Ju FY, Wang CZ, Yue XC, Fang YR, Xue HD, Chen SX. Flupentixol vs fluphenazine in schizophrenia patients: a randomized controlled trial. New Drugs and Clinical Remedies 1996;15(1):19-22.
87. Kelemen O, Nagy O, Máttyássy A, Kiss I, Janka Z, Kéri S. Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?. European Neuropsychopharmacology 2006;16(Suppl 4):S430.
88. King KG, Dittmann RW, Diehl A, Hubrich P, Maras A, Gattaz WF. Randomized double-blind trial: olanzapine vs flupenthixol. 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [EMBASE: 2002386502]
89. Kistrup K, Gerlacj J, Aaes-Jorgensen T, Larsen N. Perphenazine decanoate and cis(z)-flupenthixol decanoate in maintenance treatment of schizophrenic outpatients. Psychopharmacology 1991;105:42-8.
90. Knights A, Okasha MS, Salih MA, Hirsch SR. Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients. British Journal of Psychiatry 1979;135:515-23.
91. Kong DSG, Yeo SH. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Pharmatherapeutica 1989;5:371-9.
92. Lapierre YD, von Frenckell R. AMDP psychopathology factors in chronic schizophrenia: a clinical trial of two long-acting neuroleptics. Modern Problems of Pharmacopsychiatry 1983;20:193-203. [MEDLINE: 6137766; MEDLINE: 84013802]
93. Leff JP, Wing JK. Trial of maintenance therapy in schizophrenia. British Medical Journal 1971;3(775):599-604. [MEDLINE: 4936538; MEDLINE: 71287275]
94. Liu S. Two year follow up observations on treatments of type schizophrenia with maintenance dose of clozapine or fluanxol. Acta Medicinae Sinica 1999;12(3):266-7.
95. Liu QZ, Wang LH, Han YF, Zhou CL, Wang LH. A comparative study of fluanxol and chlorpromazine used for schizophrenia. Journal of Taishan Medical College 2000;21(2):117-21.
96. Macmillan JF. The first schizophrenic illness - presentation and short term outcome, incorporating a trial of prophylactic neuroleptic maintenance therapy versus placebo. PhD dissertation submitted to the University of Edinburgh. Edinburgh, UK: University of Edinburgh, 1984:112-40. [: SIGLE]
97. MacMillan JF, Crow TJ, Johnson AL, Johnstone EC. Short-term outcome in trial entrants and trial eligible patients. British Journal of Psychiatry 1986;148(2):128-33. [EMBASE: 1986102574; MEDLINE: 2870754; MEDLINE: 86188456;: PASCAL]
98. McCreadie RG, Wiles D, Grant S, Crockett GT, Mahmood Z, Livingston MG, et al.The Scottish first episode schizophrenia study. VII. Two-year follow-up. Scottish Schizophrenia Research Group. Acta Psychiatrica Scandinavica 1989;80(6):597-602. [MEDLINE: 2694767]
99. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study V. One-year follow-up. The Scottish Schizophrenia Research Group. British Journal of Psychiatry 1988;152:470-6. [MEDLINE: 3167396]
100. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. II. Treatment: pimozide versus flupenthixol. British Journal of Psychiatry 1987;150:334-8. [MEDLINE: 2694767]
101. Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study. VIII. Five-year follow-up: clinical and psychosocial findings. The Scottish Schizophrenia Research Group. British Journal of Psychiatry 1992;161:496-500. [MEDLINE: 1393335]
102. The Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study. III. Cognitive performance. British Journal of Psychiatry 1987;150:338-40. [MEDLINE: 3167396; MEDLINE: 89001738]
103. Mueller MJ BO. Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics. European Neuropsychopharmacology 1997;7(Suppl 2):S227-8.
104. Mueller MJ, Wetzel H, Benkert O. Differential effects of high-dose amisulpride versus flupentixol on latent dimensions of depressive and negative symptomatology in acute schizophrenia: An evaluation using confirmatory factor analysis. International Clinical Psychopharmacology 2002;17(5):249-61. [BIOSIS: 550227]
105. Muller MJ, Benkert O. Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics. 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [MEDLINE: 1487623; MEDLINE: 93139483;: PsycINFO]
106. Muller MJ, Wetzel H, Benkert O. Differential treatment effects of amisulpride versus flupentixol on latent dimensions of depressive and negative symptoms in acute schizophrenia. Schizophrenia Research 1998;29(1, 2):157. [MEDLINE: 6137766; MEDLINE: 84013802]
107. Müller MJ, Wetzel H, Benkert O. Depressive symptoms in acute psychotic disorders: evaluation methods and treatment strategies. 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. 1998. [MEDLINE: 2690890; MEDLINE: 90104929]
108. Müller MJ, Wetzel H, Benkert O. Latent dimensions of depressive and negative symptoms in acute schizophrenia: treatment effects of high dose amisulpride vs. flupentixol. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31 - Nov 4; Paris, France. 1998. [11TH: Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 1998]
109. Owen F, Bourne RC, Crow TJ, Fadhli AA, Johnstone EC. Platelet monoamine oxidase activity in acute schizophrenia: relationship to symptomatology and neuroleptic medication. British Journal of Psychiatry 1981;139:16-22. [MEDLINE: 7296184; MEDLINE: 82047583]
110. O'Regan MK, O'Donnell C, Papas A, Dell'Olio M, Purcell R, McGorry PD. 73% medication compliance needed to achieve therapeutic benefit in first episode psychosis (FEP). Australian and New Zealand Journal of Psychiatry 2005;39(Suppl 2):A74.
111. Pach J, Finkbeiner T, Wolstein J, Glaser T. Maintenance therapy with flupenthixol-decanoate in chronic schizophrenics: a one-year follow-up study. XXIst C.I.N.P. Congress. Glasgow, Scotland, UK. July 12-16, 1998. Awaiting translation.
112. Parent M, Toussaint C. Flupenthixol versus haloperidol in acute psychosis. Pharmatherapeutica 1983;3(5):354-64. [MEDLINE: 6844372; MEDLINE: 83195229]
113. Parent M, Toussaint C. Flupenthixol versus haloperidol in acute psychotic episodes [Flupentixol versus haloperidol dans les episodes psychotiques aigus]. Acta Psychiatrica Belgica 1982;82(6):617-31. [MEDLINE: 7183131; MEDLINE: 83227210]
114. Philipp M, Lesch OM, Schmauss M, Dose M, Glaser T. Comparative effectiveness of flupenthixol and risperidone on negative symptoms [Vergleichbare Wirksamkeit von Flupentixol und Risperidon auf schizophrene Negativsymptomatik]. Psychiatrische Praxis 2003;30(Suppl 2):S94-6. [MEDLINE: 14509050]
115. Reimold M, Solbach C, Noda S, Schaefer J-E, Bartels M, Beneke M, et al.Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology 2007;190(2):241-9. [MEDLINE: 17111172]
116. Rein W, Fleurot O, Turjanski S. Amisulpride improves affective symptoms in acute schizophrenia. European Neuropsychopharmacology 1998;8(Suppl 2):S231. [MEDLINE: 12633119; MEDLINE: 22521194;: PSYCINFO]
117. Rein W, Turjanski S, Fleurot O. Amisulpride in the treatment of productive schizophrenia. 10th World Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain. 1996. [EMBASE: 1995306466]
118. Ropert R, Levy L, Ropert M. Problems posed by trial use of prolonged action neuroleptics in acute psychiatric syndromes [Problemes poses par les essais d'emploi des neuroleptiques a action prolongee (N A P ) dans les syndromes psychiatriques aigus]. Annales Medico-Psychologiques 1973;1(2):259-67. [: PsycINFO]
119. Ruhrmann S, Kissling W, Lesch O-M, Schmauss M, Seemann U, Philipp M. Efficacy of flupentixol and risperidone in chronic schizophrenia with predominantly negative symptoms. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007;31(5):1012-22. [EMBASE: 2007257761; MEDLINE: 17412473;: PsycINFO]
120. Schlosser R, Grunder G, Anghelescu I, Hillert A, Ewald-Grunder S, Hiemke C, et al.Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002;46:33-40. [MEDLINE: 12633119; MEDLINE: 22521194;: PSYCINFO]
121. Simon P, Fermanian J, Ginestet D, Goujet MA, Peron Magnan P. Standard and long-acting depot neuroleptics in chronic schizophrenics: an 18-month open multicentric study. Archives of General Psychiatry 1978;35(7):893-7. [MEDLINE: 28102; MEDLINE: 78234524]
122. Singh AN. Therapeutic efficacy of flupenthixol decanoate in schizoaffective disorder: a clinical evaluation. Journal of International Medical Research 1984;12:17-22.
123. Stauning JA, Kirk L, Jorgensen A. Comparison of serum levels after intramuscular injections of 2% and 10% cis(z)-flupenthixol decanoate in viscoleo to schizophrenic patients. Psychopharmacology 1979;65(1):69-72.
124. Steuber H, Kind J, Lohrengel S, Muller P. Follow-up treatment of schizophrenic psychoses: advantages and disadvantages of long-term medication [Nachbehandlung schizophrener Psychosen: Vor- und Nachteile der Langzeitmedikation]. Arzneimittelforschung 1978;28(9):1492-3. [MEDLINE: 38806; MEDLINE: 79255780]
125. Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, et al.Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. International Journal of Neuropsychopharmacology 2007;10(3):321-33. [EMBASE: 2007223479]
126. Trueman HR, Valentine MG. Flupenthixol decanoate in schizophrenia. British Journal of Psychiatry 1974;124:58-9.
127. Tuninger E, Axelsson R, Levander S. A 3-year study of maintenance therapy with depot neuroleptics. Nordic Journal of Psychiatry 1994;48(6):409-17.
128. Tuninger E, Levander S. Large variations of plasma levels during maintenance treatment with depot neuroleptics. British Journal of Psychiatry 1996;169:618-21.
129. Turbott J, Villiger J, Hunter L. Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. British Journal of Psychiatry 1985;146:439-42.
130. Turbott J, Villiger J, Hunter L. Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome. Australian and New Zealand Journal of Psychiatry 1987;21:327-38.
131. Vaddadi KS, Gilleard CJ, Mindham RH, Butler R. A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients. Psychopharmacology 1986;88(3):362-7. [MEDLINE: 2870533; MEDLINE: 86178209]
132. Vinar O, Formankova M, Ruzicka S, Taussigova D. Flupentixol in psychoses. Controlled clinical trial. Activitas Nervosa Superior 1968;10(3):313-4. [MEDLINE: 4883239; MEDLINE: 69081705]
133. Vinar O, Taussigova D. Schizophrenic syndromes improving without neuroleptic drug treatment [Schizofrenni syndromy zlepsujici se bez neurolepticke lecby]. Ceskoslovenska Psychiatrie 1976;72(3):176-81. [MEDLINE: 77001715; MEDLINE: 786481;: PsycINFO]
134. Weiden P, Schooler NR, Severe JB, Lee JH, Schulz SC. Stabilization and DEPOT neuroleptic dosages. Psychopharmacology Bulletin 1993;29(2):269-75. [EMBASE: 1993311550; MEDLINE: 8290676; MEDLINE: 94120054]
135. Weiden P, Rapkin B, Zygmunt A, Mort T, Goldman D, Frances A. Postdischarge medication compliance of inpatients converted from an oral to a depot neuroleptic regimen. Psychiatric Services 1995;46(10):1049-54. [EMBASE: 1995306466; MEDLINE: ]
136. Weisman L, Lamberti JS, Price N. A comparison of atypical and DEPOT antipsychotic drugs in preventing jail recidivism among outpatients with schizophrenia. Schizophrenia Research 2001;49(1, 2):278. [MEDLINE: 11199942; MEDLINE: 21040726;: PsycINFO]
137. Wetzel H, Philipp M, Gattaz WF, Sauer H, Adler G, Hillert A, et al.High-dose amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology. Pharmacopsychiatry 1995;28:227. [MEDLINE: 2907629; MEDLINE: 89221175]
138. Wetzel H, Grunder G, Hillert A, Philipp M, Gattaz WF, Sauer H, et al.Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology: a double blind controlled study comparing a selective D2 like antagonist to a mixed D1 /D2 like antagonist. The Amisulpride Study Group. Psychopharmacology (Berlin) 1998;137(3):223-32. [MEDLINE: 9682999; MEDLINE: 98346529]
139. Wistedt B. A depot neuroleptic withdrawal study. A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatrica Scandanavica 1981;64:65-84.
140. Wistedt B, Palmstierna T. Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics. Journal of Clinical Psychiatry 1983;44:369-71.
141. Wistedt B. How does the psychiatric patient feel about depot treatment, compulsion or help?. Nordic Journal of Psychiatry 1995;Suppl 35:41-6.
142. Yin J, Wang H, Li Y. [San fu zuo dun yu lv bing zuo zhi liao jing shen fen lie zheng de guan cha hu li]. Heilongjiang Nursing Journal [Modern Nursing] 2005;11(15):1263-4. [: CAJ]
143. Youssef HA. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate. Clinical Neuropharmacology 1991;14(Suppl 2):S16-23. [MEDLINE: 1684308; MEDLINE: 92089871]
144. Aaes-Jorgenson A. Pharmacokinetics of oral and depot neuroleptics - clinical relevance. Symposium Espo. Feb 1, 1985.
145. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [: FLUP020600]
146. Arnt J Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998;18(2):63-101.
147. Asberg M, Montgomery SA, Perris C, Schalling D, Sedvall GA. A comprehensive psychopathological rating scale. Acta Psychiatrica Scandinavica 1978;Suppl 271:5-27.
148. Bandelow B. Effect of Flupenthixol on Negative symptoms and Depresive syndromes in Schizophrenic patients [Wirkung von Flupentixol auf Negativsymptomatik und depressive Syndrome bei schizophrenen Patienten]. In: Glaser T, Soyka M editor(s). Flupentixol. Typisches oder Atypisches Wirkspektrum?. Darmstadt, Germany: Steinkopff, 1998:66-77.
149. Barnes TRE, Curson DA. Long term depot antipsychotics. A risk benefit assessment. Drug Safety 1994;10(6):464-79.
150. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
151. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use. Therapie 1999;54(4):405-11.
152. Carney MW, Sheffield BF. Comparison of antipsychotic depot injections in the maintenance treatment of schizophrenia. British Journal of Psychiatry 1976;129:476-81.
153. Carpenter WT Jr, Buchanan RW. Schizophrenia. New England Journal of Medicine 1994;330:681-90.
154. Chouinard G, Ross-Chouinard A, Annable L. Extrapyramidal symptom rating scale. Canadian Journal of Neurological Science 1980;7:233.
155. David AS, Cutting JC. The Neuropsychology of Schizophrenia. Hove, East Sussex: Lawrence Erlbaum Associates, 1994.
156. Deeks J. Issues in the selection for meta-analyses of binary data. In: Abstracts of 8th International Cochrane Colloquium. 2000 Oct 25-28th; Cape Town, South Africa.
157. Dencker SJ, Lepp M, Malm U. Do schizophrenics well adapted in the community need neuroleptics? A depot neuroleptic withdrawal study. Acta Psychiatrica Scandinavica 1980;61(Suppl 279):64-76.
158. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
159. Department of Health, NHS Executive. Burdens of disease: a discussion document. London: HMSO, 1996.
160. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
161. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
162. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9. [PubMed: 11914310].
163. Fielding S, Lal H. Behavioural actions of neuroleptics. In: Iversen LL, Iversen SD, Snyder SH editor(s). Handbook of Psychopharmacology. Vol. 10, New York: Springer, 1978:91-128.
164. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
165. Glaser T, Sommermeyer M, Fassbinder M, Mauler F. Receptor binding of flupenthixol and other neuroleptics [Das Rezeptorbindungsprofilvon cis-Flupentixol. In: Glaser T, Soyka M (eds): Flupentixol. Typisches oderAtypisches Wirkspektrum. Steinkopff; Darmstadt, Germany]. PT06004, XXIst CINP Congress, Glasgow. 1998:6-21.
166. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. Journal of Epidemiology 1999;149:876-83.
167. Guy W. ECDEU Assessment manual for psychopharmacology. DHEW publication No (ADM). DHEW Publication No. ADM 76-338, US Government Printing Office, Washington, DC, USA, 1976. Rockville, MD: National Institute of Mental Health, 1976:124-585.
168. Hamilton M. A rating scale of depression. Journal of Neurology, Neurosurgery and Psychiatry 1960;23:56-62.
169. Harris EC, Barraclough B. Excess mortality of mental disorder. British Journal of Psychiatry July 1998;173(7):11-53.
170. Haynes RB, Taylor WD, Sackett DL. Compliance in Health Care. Baltimore: Johns Hopkins University Press, 1979.
171. Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine. American Journal of Psychiatry 2006;163:185-94.
172. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
173. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
174. Hirsch SR, Gaind R, Rohde PD. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo controlled trial. British Medical Journal 1973;1:633-7.
175. Honigfeld G, Gillis RD, Klett CJ. NOSIE-30: A treatment sensitive ward behavior scale. Psychological Reports 1962;10:799-812.
176. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE, et al.Schizophrenia: manifestations, incidence and course indifferent cultures. A World Health Organization ten-country study. Psychological Medicine Monograph Supplement 1992;20:1-97.
177. Jorgensen A, Fredricson Overo K, Hansen V. Metabolism, distribution and excretion of flupenthixol decanoate in dogs and rats. Acta Pharmacologica et Toxicologica 1971;29(2-3):339-59.
178. Jorgensen A. A sensitive and specific radioimmunoassay for cis(Z)- flupenthixol in human serum. Life Science 1978a;23:1533-42.
179. Kane JM, Woerner M, Sarantakos S. Depot neuroleptics: a comparison review of standard, intermediate and low-dose regimens. Journal of Clinical Psychiatry 1986;47(Suppl 5):30-3.
180. Kane JM, Aguglia E, Carlo Altamura A, Guiterrez JLA, Brunello N, Fleischhacker WW, et al.Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropschopharmacology 1998;8:55-66.
181. Kato L, Gozsy B, Roy PB, Trsik T. Antidepressant effects of thioxanthenes. In: Lehmann HE, Ban TA editor(s). The Thioxanthenes, Basel, Karger. Basel: Karger, 1969.
182. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda (NY): Multi-Health Systems, 1986.
183. Knapp M, Chisholm D, Leese M, Amaddeo F, Tansella M, Schene A, et al.Comparing patterns and costs of schizophrenia care in five European countries: the EPSILON study. European PsychiatricServices: Inputs Linked to Outcome Domains and Needs. Acta Psychiatrica Scandinavica 2002;105(1):42-54.
184. Krawiecka M, Goldberg D, Vaughan M. A standardised psychiatric assessment scale for rating chronic psychotic patients. Acta Psychiatrica Scandinavica 1977;55:299-308.
185. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. What does the PANSS mean?. Schizophrenia Research 2005;79:231-8.
186. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale Scores. British Journal of Psychiatry 2005;187:366-71.
187. Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Davis JM. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD008016.pub2]
188. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 2005;353(12):1209-23.
189. Mangalore R, Knapp M. Cost of schizophrenia in England. Journal of Mental Health Policy and Economics 2007;10:23-41.
190. Marshall M. Personal communication 1998. Personal communication.
191. Marshall M, Lockwood A, Adams C, Bradley C, Joy C, Fenton M. Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?. British Journal of Psychiatry 2000;39:337-49.
192. Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al.Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?. Lancet 1998;352:609-13.
193. Moher D, Schulz KF, Altman D, CONSORT Group (Consolidated Standards of Reporting Trials). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001;285(15):1987-1.
194. Murray CJL, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al.Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2197-223. [DOI: 10.1016/S0140-6736(12)61689-4]
195. Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. NICE Guideline:CGS 82 Schizophrenia (update).
196. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
197. Priest RG, Steiner J. Insanity: A study of Major Psychiatric Disorders. Plymouth: Macdonald and Evans, 1977.
198. Rust J, Golombok S. Modern Psychometrics. London: Routledge, 1989.
199. Saikia JK, Jørgensen A. Steady-state serum concentrations after cis(Z)-flupentixol decanoate in Viscoleo(R). Psychopharmacology 1983;80:371-3.
200. Sartorius N. Iatrogenic stigma of mental illness. BMJ 2002;324:1470-1.
201. Schulz KF, Chalmers I, Grimes DA, Altman DG. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynaecology journals. JAMA 1994;272:125-8.
202. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
203. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;212(Suppl 1):11-9.
204. Thornicroft G. Shunned: Discrimination Against People with Mental Illness. Oxford: Oxford University Press, 2006.
205. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):3-92.
206. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
207. David A, Adams CE, Quraishi SN. Depot flupenthixol decanoate for schizophrenia or other similar psychotic disorders. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: 10.1002/14651858.CD001470]